BNT3210
/ BioNTech
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 22, 2026
A Clinical Trial to Test if the Investigational Drug BNT3210 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker Sialyl-Tn
(clinicaltrials.gov)
- P1/2 | N=173 | Not yet recruiting | Sponsor: BioNTech SE
First-in-human • New P1/2 trial • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1